Value of Animal Models for Predicting CNS Therapeutic Action

Encyclopedia of Behavioral Neuroscience

Volumn , Issue , 2010, Pages 436-444

  McArthur, R A ^a  

^a McArthur and Associates GmbH   (Switzerland)

Author keywords

Biomarkers; Clinical outcome; Constructs; Drug discovery; Homology; Imaging; Pharmacogenetics; Pharmacological isomorphism; Phenotype; Translational research; Validity

Indexed keywords

EID: 77954118049     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-045396-5.00021-X     Document Type: Chapter

References (32)

1. Psychopharmacology (Berl) 2005, 180:581-788. Brain Imaging.
2. Chudasama Y., Robbins T.W. Functions of frontostriatal systems in cognition: Comparative neuropsychopharmacological studies in rats, monkeys and humans. Biological Psychology 2006, 73:19-38.
3. Neuropsychopharmacology 2009, 34:1-243. CNS Drug Discovery and Development: Challenges and Opportunities.
4. Cryan J.F., Holmes A. Model organisms: The ascent of mouse: Advances in modelling human depression and anxiety. Nature Reviews Drug Discovery 2005, 4:775-790.
5. Geyer M.A., Markou A. Animal models of psychiatric disorders. Psychopharmacology, the Fourth Generation of Progress 1995, 787-798. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
6. Gottesman T.D., Gould The endophenotype concept in psychiatry: Etymology and strategic intentions. American Journal of Psychiatry 2003, 160:636-645.
7. Neuropsychopharmacology 2008, 33:2047-2092. Institute of Medicine Forum on Drug Discovery, Development, and Translation.
8. Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004, 1:189-195.
9. Katz R. FDA: Evidentiary standards for drug development and approval. NeuroRx 2004, 1:307-316.
10. Markou A., Chiamulera C., Geyer M.A., Tricklebank M., Steckler T. Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology 2009, 34:74-89.
11. McArthur R., Borsini F. Animal models of depression in drug discovery: A historical perspective. Pharmacology Biochemistry and Behavior 2006, 84:436-452.
12. Animal and Translational Models for CNS Drug Discovery, Vol. 1: Psychiatric Disorders 2008, Academic Press, San Diego, CA. R.A. McArthur, F. Borsini (Eds.).
13. Animal and Translational Models for CNS Drug Discovery, Vol. 2: Neurological Disorders 2008, Academic Press, San Diego, CA. R.A. McArthur, F. Borsini (Eds.).
14. Animal and Translational Models for CNS Drug Discovery, Vol.3: Reward Deficit Disorders 2008, Academic Press, San Diego, CA. R.A. McArthur, F. Borsini (Eds.).
15. Perlis R.H., Moorjani P., Fagerness J., et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: Association of TREK1 and treatment resistance in the STAR[*]D study. Neuropsychopharmacology 2008, 33:2810-2819.
16. Robbins T.W. Homology in behavioural pharmacology: An approach to animal models of human cognition. Behavioural Pharmacology 1998, 9:509-519.
17. Rogers D.C., Jones D.N., Nelson P.R., Jones C.M., Quilter C.A., Robinson T.L., Hagan J.J. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behavioural Brain Research 1999, 105:207-217.
18. Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives 1991, Cambridge University Press, Cambridge. P. Willner (Ed.).
19. A guide to drug discovery. An on-going series from Nature Reviews Drug Discovery. 2003-2008. http://www.nature.com/nrd/series/drugdiscovery/index.html.
20. A comprehensive bibliography of preclinical and clinical CANTAB applications. http://www.cantab.com/science/bibliography.asp.
21. A Research Agenda for DSM-V, 2002. http://www.appi.org/book.cfm?id=2292.
22. Code of Federal regulations (Title 21). Good Laboratory Practice for nonclinical laboratory studies. http://www.nal.usda.gov/awic/legislat/21cfr97.htm.
23. Deconstructing Psychosis. 2007. http://www.appi.org/book.cfm?id=2653.
24. European Consensus-Platform for Alternatives to Animal Experiments. http://www.emea.europa.eu/pdfs/human/swp/072895en.pdf.
25. European Medicines Agency. Replacement of animal studies by in vitro models (1997). http://www.ecopa.eu/.
26. Guidance for industry. Animal models - essential elements to address efficacy under the animal rule (Draft 2009). http://www.fda.gov/cder/guidance/8324dft.pdf.
27. Guidance for industry. Content and format of investigational new drug applications (INDs) for Phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products. (1995). http://www.fda.gov/cder/guidance/phase1.pdf.
28. Guidance for industry, investigators, and reviewers - Exploratory IND studies. (2006). http://www.fda.gov/cder/guidance/7086fnl.pdf.
29. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. 2004. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
30. Inspections and Standards of the UK Medicines and Healthcare Products Regulatory Agency. http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodLaboratoryPractice/index.htm.
31. NIH Roadmap for Medical Research. http://nihroadmap.nih.gov/overview.asp.
32. Present status of GlaxoSmithKline Phase III trial of rosiglitazone in an Alzheimer population stratified by APOE4 genotype. http://clinicaltrials.gov/ct2/show/NCT00550420?term=rosiglitazone+AND+alzheimer&rank=3.